HEMO-CAR-T therapy(Hemogenyx)

N/A

Report date: 2025/01/23 17:32:25

Base Information

Drug NameHEMO-CAR-T therapy(Hemogenyx)

Drug Alias NameAnti-FLT3 CAR-T cells therapy(Hemogenyx)HG-CT-1

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityTyrosine-protein kinase receptor FLT3 modulators

TargetsTyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesHemogenyx Pharmaceuticals PLC

China Registration ClassN/A

Develop Information

Active CompaniesHemogenyx Pharmaceuticals LLC Hemogenyx Pharmaceuticals PLC

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A